Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,739.60
(
-1.63%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
106.58
(
5.89%
)
Bitcoin
71,059.66
(
-3.90%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 128945

Friday, 10/21/2011 12:10:35 PM

Friday, October 21, 2011 12:10:35 PM

Post# of 257257
It remains to be seen whether ribavirin will be part of ABT’s all-oral HCV combination, when all is said and done. The components will likely include ABT-450 (a PI), ABT-267 (an NS5A inhibitor), and one of the non-nukes (ABT-072 or ABT-333).

ABT-450 requires boosting with ritonavir, so there are at least four drugs in the cocktail (and possibly five) if you count ritonavir.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now